The impact of sodium‐glucose cotransporter‐2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer

• DOI: 10.1111/jgh.16498
• Publication Date: 2024-02-01T00:44:45Z
• Authors: Cho‐Han Chiang; Cho‐Hung Chiang; Yuan Ping Hsia; Aunchalee Jaroenl...; Chuan‐Sheng Horng; Kit Yee Wong; Shih‐Syuan Wang; Yu‐Cheng Chang; Brian Shiian Chen; Yu‐Ze Luan; Chun‐Hao Wang; Tomas G. Neilan; Cho‐Hsien Chiang; Cheng‐Ming Peng; Her‐Shyong Shiah
• Keywords: Male; 0301 basic medicine; Middle Aged; Adenocarcinoma; Survival Rate; Cohort Studies; 03 medical and health sciences; Treatment Outcome; Diabetes Mellitus, Type 2; Humans; Female; Colorectal Neoplasms; Sodium-Glucose Transporter 2 Inhibitors; Retrospective Studies; Aged

Abstract Background and Aim Patients with type 2 diabetes mellitus (T2DM) have a higher risk of colorectal cancer (CRC), those diagnosed CRC poorer prognosis compared individuals normal glucose levels. The inhibition sodium‐glucose cotransporter (SGLT2) channels has been associated reduction in tumor proliferation preclinical studies. We aimed to investigate the impact inhibitors (SGLT2i) on outcome T2DM patients cancer. Methods performed retrospective cohort study comprising adult adenocarcinoma. SGLT2i recipients were matched non‐SGLT2i 1:1 ratio based age, sex, stage. primary was overall survival (OS) progression‐free (PFS), secondary outcomes previously reported serious adverse events SGLT2i. Results identified 1347 adenocarcinoma, from which 92 cohort. Compared recipients, had rate 5‐year OS (86.2% [95% CI: 72.0–93.5] vs 62.3% 50.9–71.8], P = 0.013) PFS (76.6% 60.7–86.7] 57.0% 46.2–66.4], 0.021). In Cox proportional hazard analyses, 50–70% all‐cause mortality disease progression. not an increased events. Conclusion